Secondary analysis
Expanding the Spectrum of Transcatheter Edge-to-edge Repair (TEER) Suitability
- Secondary analysis of the EXPAND G4 prospective single-arm study
- global
- multicentre
- postapproval
- independent core laboratory
Authors' conclusion
Patients previously deemed TEER unsuitable can be safely and effectively treated with the mitral TEER fourth-generation device.
Study context
- Population
- Patients with mitral regurgitation (MR) treated with the MitraClip G4 System
- Participants
- 1,164 patients
- Comparison
- TEER outcomes across HVC TEER-suitability categories
- Risk of stenosis (RoS)n = 56
- RoIRn = 54
- MMRn = 326
- TEER-suitable (TS)n = 303reference
Primary result
As reported in the abstract
MR reduction (≤1+; ≤2+ for RoIR) · 30 days
Further findings
NYHA class I or II, 30 days vs baseline
30 days
Baseline
All-cause mortality · 30 days
| Outcome | RoS | RoIR | MMR | TS |
|---|---|---|---|---|
| Change in KCCQ score · 30 days | +27 ± 26 | +16 ± 26 | +19 ± 26 | +19 ± 24 |
- All-cause mortality — Major adverse events low in all groups
- <3%
Original publication
Expanding the Spectrum of TEER Suitability. JACC Cardiovasc Interv. Published 26 June 2023. doi:10.1016/j.jcin.2023.05.014
Summarised from the published abstract; every number is checked against it